Brivanib alaninate

DB11865InvestigationalSmall molecule

Brivanib alaninate has been investigated for the treatment of Colorectal Cancer.

Mechanism: Pharmacologically active on Vascular endothelial growth factor receptor and Fibroblast growth factor receptor
Curator reviewed
Formula / weight: C₂₂H₂₄FN₅O₄ · 441.463 g/mol (avg)
Code names: BMS-582664 · BMS-582664-02

Resolves to

Compound

Structure

InChIKeyLTEJRLHKIYCEOX-OCCSQVGLSA-NSMILESC[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brivanib alaninate, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.